G1 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2015
Revenue	82.51	51.3	31.48	45.29	0	Upgrade
Revenue Growth (YoY)	60.84%	62.98%	-30.49%	-	-	Upgrade
Cost of Revenue	7.2	3.75	2.02	0	0	Upgrade
Gross Profit	75.32	47.55	29.46	45.29	0	Upgrade
Selling, General & Admin	71.13	100.42	95.69	68.49	40.04	Upgrade
Research & Development	43.71	83.32	76.23	73.27	89	Upgrade
Operating Expenses	114.84	183.73	171.92	141.76	129.04	Upgrade
Operating Income	-39.53	-136.18	-142.46	-96.48	-129.04	Upgrade
Interest Expense / Income	10.04	10.43	4.67	1.78	0	Upgrade
Other Expense / Income	-4.71	-0.75	0.3	-0.41	-6.59	Upgrade
Pretax Income	-44.85	-145.86	-147.43	-97.84	-122.45	Upgrade
Income Tax	3.12	1.7	0.93	1.41	0	Upgrade
Net Income	-47.97	-147.56	-148.35	-99.25	-122.45	Upgrade
Shares Outstanding (Basic)	52	44	42	38	37	Upgrade
Shares Outstanding (Diluted)	52	44	42	38	37	Upgrade
Shares Change	18.58%	4.01%	10.73%	1.01%	12.55%	Upgrade
EPS (Basic)	-0.93	-3.38	-3.54	-2.62	-3.27	Upgrade
EPS (Diluted)	-0.93	-3.38	-3.54	-2.62	-3.27	Upgrade
Free Cash Flow	-38.34	-129.13	-132.11	-83.59	-102.29	Upgrade
Free Cash Flow Per Share	-0.74	-2.96	-3.15	-2.21	-2.73	Upgrade
Gross Margin	91.28%	92.69%	93.60%	100.00%	-	Upgrade
Operating Margin	-47.91%	-265.45%	-452.59%	-213.04%	-	Upgrade
Profit Margin	-58.13%	-287.63%	-471.32%	-219.18%	-	Upgrade
Free Cash Flow Margin	-46.46%	-251.70%	-419.71%	-184.59%	-	Upgrade
EBITDA	-34.3	-134.9	-142.29	-95.48	-122.09	Upgrade
EBITDA Margin	-41.57%	-262.95%	-452.06%	-210.85%	-	Upgrade
Depreciation & Amortization	0.51	0.53	0.47	0.58	0.36	Upgrade
EBIT	-34.81	-135.43	-142.76	-96.07	-122.45	Upgrade
EBIT Margin	-42.19%	-263.99%	-453.55%	-212.14%	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).